What Offspring Biosciences does

Offspring Biosciences AB is a Swedish contract research organization founded in 2012 and headquartered in Södertälje, Sweden, providing specialized antibody validation services to the biotechnology and pharmaceutical industry. The company's core offering is the proprietary Tissue Insights™ Solution, a tissue-first translational research methodology that uses microscopic immunofluorescence analysis to validate antibody drug candidates directly in human disease tissue rather than relying on animal models. This approach is designed to reveal true target distribution, specificity, and off-target liabilities before sponsors commit to expensive GLP-TCR studies and clinical development, addressing what the company describes as the industry-wide translational gap.

The company's business model is project-based professional services revenue, with custom quote-based pricing per engagement and multi-year contract cadences typical of specialized CRO work. Offspring operates a direct sales-led go-to-market, offering enterprise biotech and pharma clients direct access to senior scientific partners rather than routing through account management layers. The firm has 11–50 employees and markets a small expert team (including Åsa Johansson, Dan Dunnemark, and Mia Nilsson Cedwell) with positions explicitly contrasting its consultative scientific depth against larger CROs.

Offspring's primary customer segment is enterprise biotechnology and pharmaceutical companies developing antibody therapeutics, with use cases spanning antibody drug candidate validation, tissue cross-reactivity studies, IND-enabling programs, target distribution analysis, specificity assessment, and off-target liability identification. BioArctic, a Swedish biotech commercializing Alzheimer's and Parkinson's therapeutics, is the company's most prominently disclosed reference customer and long-standing scientific collaborator. The company maintains a multi-channel marketing presence (website, LinkedIn, X, YouTube, Instagram, newsletter) emphasizing thought leadership around translational research challenges.

Name

Offspring Biosciences

Legal name

Offspring Biosciences AB

Website

https://www.offspringbiosciences.se/

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Offspring Biosciences is a Swedish contract research organization founded in 2012 that provides specialized antibody validation services to biotechnology and pharmaceutical companies using its proprietary Tissue Insights™ tissue-first translational research platform.

Ownership category

akta.pro rank

Product category

Contract Research Services (Antibody CRO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Antibody validation services
• Tissue cross-reactivity
• Translational research services
• Immunofluorescence analysis
• Antibody drug development

Headquarters

HQ city

Södertälje

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services: CRO services for antibody validation and tissue analysis. Provides specialized contract research in cell and tissue focused R&D, supporting the biotechnology and pharmaceutical industry with scientific excellence. Revenue derived from project-based research contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Offspring Biosciences is a specialized antibody Contract Research Organization (CRO) that validates antibody drug candidates in human disease tissue using its proprietary Tissue Insights™ Solution. Through microscopic immunofluorescence analysis, the company reveals true target distribution, specificity, and off-target liabilities of antibody candidates before clinical commitment, providing biotech and pharma clients with decisive go/no-go signals for IND-enabling programs. Operations are delivered from a single research facility in Södertälje, Sweden, with direct senior scientific partner engagement on every project.

Product overview

Offspring Biosciences is a specialized antibody Contract Research Organization (CRO) offering a single unified platform called Tissue Insights™ Solution. This proprietary platform provides tissue-first translational research services, using human disease tissue analysis to validate antibody drug candidates. The company focuses on closing the translational gap between animal models and human clinical outcomes by providing immunofluorescence analysis, tissue cross-reactivity testing, and strategic go/no-go decision support for biotechnology and pharmaceutical clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Tissue Insights™ Solution Proprietary tissue-first translational research methodology and service that validates antibody drug candidates in human disease tissue using microscopic immunofluorescence analysis. The solution reveals true target distribution, specificity, and potential off-target liabilities before clinical commitment, providing biotech and pharmaceutical clients with decisive go/no-go signals for IND-enabling and tissue cross-reactivity programs.

Quantifiable outcome

• Delivers insights weeks faster than larger CRO giants

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

One partnership is on record.

• BioArcticcoreStrategic or Co-development PartnerLong-standing scientific collaboration in the successful development of novel treatments for Alzheimer's and Parkinson's disease. This collaboration serves as a key proof point for Offspring Biosciences' tissue-first translational research methodology, demonstrating their ability to contribute to successful drug development programs for neurodegenerative diseases.

Scale indicators1 record

Recent moves1 record

Expansion highlights3 records

Broad incumbents

• Abcam (Danaher): Abcam, now part of Danaher, manufactures and validates antibodies and offers validation services for therapeutic antibody developers. Comparable as a larger incumbent in antibody validation with overlapping tissue-based and specificity-assessment capabilities.
• Cell Signaling Technology: Cell Signaling Technology develops and validates highly characterized antibodies used in disease mechanism and translational research, including IHC-grade reagents for pharma. Comparable to Offspring's antibody validation and tissue-specificity work, though distributed as products rather than services.
• Fortrea (formerly LabCorp Drug Development): Fortrea is a large CRO providing preclinical and clinical development services to pharma and biotech, with capabilities spanning bioanalytical, biomarkers, and translational sciences. Overlaps with Offspring in preclinical and bioanalytical service lines serving antibody drug developers.
• Eurofins Discovery: Eurofins Discovery, part of Eurofins Scientific, is a large preclinical CRO offering antibody characterization, IHC, immunohistochemistry, and tissue-based assays among a broad service menu. Comparable as an incumbent preclinical CRO with overlapping tissue-validation capabilities.
• Charles River Laboratories: Charles River is a global preclinical CRO with research models, safety assessment, and discovery services that include antibody and tissue-based work. Comparable as a broad incumbent serving the same antibody/biotech clients with end-to-end preclinical capabilities.
• NeoGenomics: NeoGenomics provides clinical and biomarker testing services including IHC and tissue-based assays for pharma R&D and clinical trials. Comparable as a broader biomarker/tissue-focused service provider to biopharma, overlapping with Offspring's translational tissue work.

Direct peers

• Crown Bioscience (JSR Life Sciences): Crown Bioscience is a translational and preclinical CRO offering biomarker analysis, IHC, and translational research services to antibody and oncology programs. It directly overlaps with Offspring on preclinical tissue-based translational validation for drug development.
• HistoCyte Laboratories: HistoCyte provides tissue-based control materials and histopathology services to pharma, including immunohistochemistry and tissue cross-reactivity work. It is the closest direct comp to Offspring in combining a tissue-first specialty with antibody/diagnostic validation for pharma sponsors.

Emerging players

• Bethyl Laboratories (Fortis Life Sciences): Bethyl Laboratories, part of Fortis Life Sciences, develops and validates antibodies for research use, including IHC applications. Comparable in antibody validation and specificity science, though primarily a reagent supplier rather than full translational CRO.
• Protagen (now part of Sapidyne Instruments portfolio) / Protagen Diagnostics: Protagen has historically provided biomarker discovery and immunoassay-based translational services to pharma, including tissue-based biomarker work. Comparable as an emerging specialist in biomarker and translational immunology services overlapping with Offspring's tissue-validation thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/OffspringBioAB
• YouTubeyoutube.com/channel/UCiSGlL0FCSvn50eQCy_Ph-w
• LinkedInlinkedin.com/company/offspring-biosciences-ab
• Instagraminstagram.com/offspringbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Offspring Biosciences